NEW YORK (GenomeWeb) – Biodesix today announced that UnitedHealthcare has issued a positive coverage decision for the VeriStrat test for advanced non-small cell lung cancer. 

UnitedHealthcare covers 44.7 million lives in the US. 

VeriStrat is a blood-based proteomic test that provides prognostic and predictive data to help guide treatment of patients with advanced NSCLC. Those with VeriStrat Poor test results have a shorter medical overall survival that those with VeriStrat Good results, Boulder, Colorado-based Biodesix said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.